Carlyle Expands Device Venture Finance Group

When most industry people hear of The Carlyle Group, they think of it exclusively as a buyout group, and indeed leveraged buyouts are an important part of the global private equity firm's business. But many are surprised to learn that Carlyle has a venture and growth capital operation that maintains a strong commitment to investing in the medical device sector.

When most industry people hear of The Carlyle Group, they think of it exclusively as a buyout group, and indeed leveraged buyouts are an important part of the global private equity firm’s business. But many are surprised to learn that Carlyle has a venture and growth capital operation that maintains a strong commitment to investing in the medical device sector. In fact, Carlyle recently announced that it is expanding its health care venture operations to the West Coast—they had previously been based in New York and Washington, DC—with the opening of a San Francisco office to be closer to the hub of early-stage medical technology activities in the Bay area. Carlyle is currently investing in devices out of its new $605 million venture and growth fund.

"Medical device investing is the core of what we do in health care venture capital at Carlyle," says Ryan M. Schwarz, managing director and head of the firm’s venture and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By 

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By 

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

More from In Vivo

US Health System Redesign Critical, NAM’s Medical Experts Warn Trump Government

 
• By 

The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.

Podcast: “Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System

 

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

 
• By 

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.